rather than hypercholesterolaemia, may exert a deleterious effect on graft and patient survival.
Abstract
Hyperlipidaemia is a frequent complication after renal transplantation. As to whether total cholesterol (TC) and triglyceride levels are risk factors for cardiovascular disease and graft survival is controversial. The prevalence of hypercholesterolaemia in the transplanted population in Spain has increased over the years, going from 38.8% in 1990 to 48% in 1998. In contrast, the prevalence of hypertriglyceridaemia being 20%, has not shown any significant variation. Transplant recipients with high cholesterol were characterized by increased age, lower proportion of males, higher mean body mass index, lower proportion of HCV antibodies, reduced time on dialysis and diabetes. Patients with high cholesterol were more frequently treated with cyclosporine þ MMF þ prednisone and less frequently treated with tacrolimus þ MMF þ prednisone. Hypertriglyceridaemia was more frequent in patients treated with cyclosporine þ MMF þ prednisone, and these patients showed significantly higher creatinine plasma levels at 1 year and were more frequently treated with lipid-lowering agents. Hypertriglyceridaemia at 3 months after transplantation is associated with worse graft survival (RR 1.078; CI 1.07-1.143; P ¼ 0.011) and greater cardiovascular mortality (RR 1.265; CI 1.20-1.428; P ¼ 0.0002), while treatment with statins has a protective effect on the graft survival (RR 0.64; CI 0.512-0.888; P ¼ 0.0051). In conclusion, in the renal transplant population in Spain, hypertriglyceridaemia
Introduction
Large studies in the general population have demonstrated that there is a significant association between increase in total cholesterol (TC) and onset of cardiovascular disease (CVD), which has not been demonstrated with the isolated increase of triglycerides. In addition, it has been reported that a decrease in the TC reduces death by improving CVD both in primary as well as in secondary prevention [1, 2] .
Hyperlipidaemia is a frequent complication after renal transplantation, with a prevalence ranging from 60 to 70% in the different series [3, 4] . Thus, the lipid profile that characterizes chronic renal failure [increased triglycerides, decreased high density lipoprotein (HDL)-cholesterol, normal TC and normal low density lipoprotein (LDL)-cholesterol] changes after transplantation into a type IIA hyperlipidaemia (increased TC, increased LDL-cholesterol, normal or slightly increased triglycerides, normal HDLcholesterol). Several factors are associated with the appearance of these lipid abnormalities such as age, male gender, obesity, diabetes, proteinuria, treatment with antihypertensive and immunosuppressive drugs. There are several studies that support the fact that dyslipidaemia is a cardiovascular risk factor in the transplanted population [4] [5] [6] , even though other authors have not found this association [7] .
In organ transplantation, dyslipidaemia may be considered as a factor that influences chronic allograft nephropathy (CAN). There is some evidence that supports its pathogenic role, since the vascular lesions that characterize CAN are similar to those of arteriosclerosis [8] . On the other hand, it has been reported that dyslipidaemia favours the deterioration of renal function in CAN [10, 11] , and that there are more lipid abnormalities in patients with CAN than in patients without CAN [12, 13] . Regarding the relationship between dyslipidaemia and the time course of the graft function, there are also discrepancies since there are studies that relate it with triglycerides but not with TC [14, 15] .
However, it is not clear if the course of CAN improves when dyslipidaemia is treated and what role statin therapy may play.
Subjects and methods
Hypercholesterolaemia at 3 months was defined as cholesterol 240 mg/dl and/or treatment with lipid-lowering agents, while hypertriglyceridaemia at 3 months was defined as triglycerides 200 mg/dl.
Results

Hypercholesterolaemia
The prevalence of hypercholesterolaemia was 43.3%, with significant differences between years of transplantation; the incidence by year was 38.8% in 1990, 40.4% in 1994 and 48.0% in 1998 (P<0.0001). Table 1 compares baseline recipient characteristics. Transplant recipients with high cholesterol were characterized by increased age, lower proportion of males, higher body mass index, lower proportion of HCV antibodies, reduced time on dialysis, diabetes and lower percentage of non-cadaveric donors (data not shown). Table 1 also shows the intention-to-treat analysis of the calcineurin inhibitor immunosuppressive regimen at the time of transplantation between patients with cholesterol 240 mg/dl or treated with statins and the other patients. Patients with high cholesterol were more frequently treated with cyclosporine þ MMF þ prednisone and less frequently with tacrolimus þ MMF þ prednisone (data not shown). The acute rejection incidence was slightly but significantly lower among recipients with hypercholesterolaemia (cholesterol >240 mg%, 29.8% vs cholesterol <240 mg%, 34.6%; P ¼ 0.003). Creatinine plasma levels and proteinuria at 3 months and 1 year were significantly lower in the hypercholesterolaemia group (creatinine at 1 year: cholesterol >240 mg%, 1.7±0.75 vs cholesterol <240 mg%, 1.61±0.67, P ¼ 0.0007), (proteinuria at 1 year: cholesterol >240 mg%, 0.33±0.81 vs cholesterol <240 mg%, 0.33±0.71).
No significant differences were found for the rest of the variables analysed.
Hypertriglyceridaemia
In contrast to hypercholesterolaemia, the incidence of hypertriglyceridaemia did not change significantly between years of transplantation and was 20.7% for the overall study period. The incidence by year was 18.8% in 1990, 19.4% in 1994 and 22.5% in 1998 (P ¼ 0.9).
Comparing baseline recipient characteristics between patients with triglycerides 200 mg/dl vs the other patients shows a higher percentage of prior transplantation, higher last panel reactive antibodies, diabetes and lower frequency of non-cadaveric donor characterized hypertriglyceridaemia (data not shown). Hypertriglyceridaemia was more frequent in patients treated with cyclosporine þ MMF þ prednisone.
In the follow-up, patients with higher levels of triglycerides showed higher plasma creatinine levels at 1 year and were more frequently treated with lipidlowering agents. No significant differences were found for the other variables. Table 2 shows the Cox regression analysis results related to graft and patient survival. Hypertriglyceridaemia at 3 months was significantly associated with graft survival. Hypertriglyceridaemia at 1 year and hypercholesterolaemia at 3 months and 1 year did not show any significant effect on graft or patient survival. It is interesting to stress that treatment with statins was found to be a graft survival predictor, independently of the effect of treatment with MMF.
Effect of triglycerides and treatment with statins on graft and patient survival
Subjects with diabetes as primary disease, glucose >140 mg/dl or glucose lowering treatment between 3 months and 3 years post-transplantation were found to have a significantly higher risk for graft loss and patient death than the rest of the sample. Table 3 shows factors found to be significantly associated with cardiovascular survival (i.e. death due to CVD).
Discussion
After transplantation, an early increase in TC, LDL and triglycerides is observed. These facts are related to the rapid increase of body weight after transplantation and have been basically ascribed to the immunosuppressive regimens based on anticalcineurinics and corticosteroids, drugs that are capable of causing each of them a dose-dependent and reversible increase of serum lipids [16] [17] [18] . The prevalence of hypercholesterolaemia in our renal transplant population has shown a progressive increase over the years, going from 38.8% in 1990 to 48% in 1998, perhaps in relation to the change of dietary habits in Spain. Despite this, hypercholesterolaemia it is still lower than the prevalence described in other countries [3, 4] . On the contrary, hypertriglyceridaemia prevalence being 20%, has not shown any significant variation over these years. The increase in hypercholesterolaemia cannot be explained by the progressive introduction of tacrolimus in place of cyclosporine. Even more, it The effects of hyperlipidaemia on graft and patient outcome in renal transplantation iii69 seems that tacrolimus induces less dyslipidaemia than cyclosporine. In fact, a recent study demonstrated that the conversion from cyclosporine to tacrolimus was associated with a significant decrease in LDLcholesterol, apolipoprotein B, triglycerides and the oxidated fraction of LDL-cholesterol [19] . Our study agrees with these data since the immunosuppressive treatment regimens based on cyclosporine are indeed associated with a greater prevalence of both hypercholesterolaemia as well as hypertriglyceridaemia.
In this study, as in others [14, 15] , the presence of hypercholesterolaemia was not associated with worse graft or patient survival. A possible explanation would be that, in our population, the patients with hypercholesterolaemia had a lower incidence of acute rejection, better creatinine levels and lower proteinuria at 1 year, all these endpoints have a favourable prognostic value that may be explained precisely from the greater use of statins in hypercholesterolaemic patients. Statins have an immunomodulator effect that could lead to a lower incidence of acute rejection, as has been observed by Kobashigawa et al. [20] in cardiac transplantation. It is thus possible that the harmful effect of hypercholesterolaemia is masked by the greater use of statins precisely in these patients. On the other hand, it seems that the increase in LDLcholesterol more than TC is really associated with a worse prognosis [21] .
Post-transplantation hypertriglyceridaemia is a negative prognostic factor for both patient as well as graft survival [14, 21] . Even though in our study, patients with hypertriglyceridaemia also received statins with greater frequency, the hypertriglyceridaemia at 3 months was associated with higher levels of plasma creatinine at 1 year, worse graft survival and greater cardiovascular mortality. On the contrary, the prognostic value of hypertriglyceridaemia disappeared at 1 year after transplantation. The most probable explanation is that treatment with statins in most of the cases was initiated beyond the third posttransplantation month, masking the prognostic value of hypertriglyceridaemia after that time.
Parallel with the increase in the prevalence of hypercholesterolaemia, the use of statins is increasingly more common in renal transplant recipients in Spain. In this study, use of statins after renal transplantation was associated with a clear protective effect on graft survival. There is increasing evidence of the beneficial role of these drugs in the field of organ transplantation. A pilot study observed that under conventional immunosuppression, patients treated with statins presented a lower incidence of acute rejection [20] , although these data have not been confirmed in multicentre studies [22] . However, administration of statins in the immediate post-transplantation period improves the cardiovascular profile [23] and is associated with an improvement in renal graft survival of up to 24% in some studies [24] .
In conclusion, hypertriglyceridaemia at 3 months after transplantation is associated with worse graft survival and with greater cardiovascular mortality, while treatment with statins has a protective effect on graft survival. Year of transplantation was not included because it was not significant. Treatment with statins during the first year, MMF and cyclosporine/tacrolimus at the time of transplantation, triglycerides at 1 year and cholesterol at 3 months and 1 year were not statistically significant. Ref., reference.
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